Lilly’s retatrutide beats Ozempic in head-to-head trial
Eli Lilly, a dominant force in the obesity and type 2 diabetes market, has just beaten its biggest rival, with …
Post
-
-
IDWeek 2026: BNT163 poised to fulfil a substantial unmet need for genital herpes
At the 15th annual IDWeek conference in Washington DC, Federico Mensa of BioNTech presented data on BNT163, a trivalent mRNA …
-
ESMO26: US and FDA movements to improve oncology trials a positive signal
Since the Trump Administration took office in the White House, there has been an uptick in the number of guidance …
-
Walmart and Care Access to open three clinical trial centres in US
The Walmart Healthcare Research Institute (WHRI) and Care Access are set to launch three further clinical trial centres in the …
-
Vanda reports Phase III tradipitant trial data in GLP-1-associated vomiting
Vanda Pharmaceuticals has reported positive results from the Phase III clinical trial, Study 3601 (VP-VLY-686-3601), assessing its oral therapy Nereus …
-
ESMO26: Other skin cancer advances beyond groundbreaking cancer vaccine
Arguably the most impactful readout in skin cancer in recent months was MSD and Moderna’s melanoma cancer vaccine data. At the …
-
ESMO26: Intismeran sets new benchmark in adjuvant melanoma
At the 2026 European Society for Medical Oncology (ESMO) Congress, full results from Merck and Moderna’s Phase III INTerpath-001 trial …
-
Retatrutide cost in 2026: What a research vial really costs and why the cheapest listing is a red flag
Search for retatrutide online and you’ll find prices that vary wildly. One listing asks a fair amount, the next asks …
-
IDWeek 2026: meropenem-pilabactam successfully targets critical priority pathogens
At the 15th annual IDWeek conference in Washington DC, Rienk Pypstra, MD, chief medical officer of Antabio, presented data on …
-
ESMO26: Promising results seen for opamtistomig in advanced heavily treated epNEC
At the European Society for Medical Oncology (ESMO) Congress 2026, results were presented from the pivotal, registrational Phase IIb study …
-
ESMO26: Breast cancer treatment landscape continues to be redefined
Breast cancer is the most common cancer among women globally, accounting for roughly 25% of all female cancer diagnoses; however, …
-
Mirum reports Phase II zilurgisertib trial data in paediatric FOP
Mirum Pharmaceuticals has reported positive data from cohort 2 of the pivotal Phase II PROGRESS trial assessing Atebrioz (zilurgisertib) in …
-
First patient dosed in Enanta’s Phase IIb/III trial for RSV
Enanta Pharmaceuticals has dosed the first patient in its global Phase IIb/III RESOLVE trial assessing zelicapavir in high-risk adult outpatients …
-
ESMO26: The “paradigm-shifting” readouts in endometrial & ovarian cancer
At this year’s European Society for Medical Oncology (ESMO) Congress, attention has shifted toward indications that have traditionally received less …
-
ESMO26: Sac-TMT’s OptiTROP-Lung04 survival gain holds, putting the onus on MSD
On 25 October 2026, Professor Wenfeng Fang presented the final overall survival (OS) analysis of the Phase III OptiTROP-Lung04 trial …
